This study analyzes the electrophysiological cause and behavioral consequence of dopaminergic cell loss in a knock-in mouse strain bearing hypersensitive nicotinic 4 receptor subunits ("L9'S mice"). Adult brains of L9'S mice show moderate loss of substantia nigra dopaminergic neurons and of striatal dopaminergic innervation. Amphetamine-stimulated locomotion is impaired, 
Introduction
Neuronal nicotinic receptors (nAChRs) containing 4 subunits are highly expressed on cell bodies of dopaminergic neurons in the midbrain (2) . nAChRs on dopaminergic neurons regulate dopamine release in striatum and frontal cortex (20, 26) , and play a role in nicotine addiction and motor control. Chronic treatment with nicotine facilitates dopamine release and locomotor responses, which is consistent with an upregulation of nAChRs in dopaminergic neurons (24). Chronic continuous treatment with nicotine does not alter locomotor behavior (30) but induces upregulation of dopamine D2 receptors, which was interpreted as a consequence of downregulation of dopamine turnover (8) . Thus, chronic continuous administration of nicotine seems to suppress net dopamine release, perhaps via desensitization of nAChRs on dopaminergic neurons.
This study analyzes the only known instance of dopaminergic cell death caused by chronic activation of nicotinic receptors (17). The pathology occurs in knock-in mice carrying a leucine to serine mutation at the 9' position of the pore-lining second transmembrane domain (M2) in the 4 subunit. To retain viability, we work with (a) a strain that displays reduced expression of the hypersensitive allele, because of a deliberate insertion of the neomycin selection cassette in an intron adjoining the mutated exon; and (b) with heterozygotes of this strain. These viable and fertile heterozygous mice are termed "L9'S". L9'S mice do not show a significant reduction of dopaminergic neurons during embryonic development but have a reduction of amphetamine-induced locomotion as they age (17). In addition, L9'S mice display increased anxiety. Following low doses of nicotine, L9'S mice display seizures and Straub tail (6, 17) .
Here, we show that adult L9'S mice show a moderate and specific loss of dopaminergic neurons in substantia nigra, while dopaminergic neurons in the ventral tegmental area and noradrenergic neurons in locus coeruleus show no gross abnormalities. Also, there is a significant reduction of dopaminergic innervation to caudate and putamen but not nucleus accumbens. These morphological changes are paralleled by a significant reduction in amphetamine-induced locomotor activity. We believe that the loss of dopaminergic neurons in substantia nigra is associated with an increased excitation during exposure to agonists, as evidenced by recordings from dopaminergic neurons in acute midbrain slices. Thus, although this 4-hypersensitive genotype is viable and fertile, it displays dopaminergic cell death as a consequence of excessive nicotinic stimulation.
Materials and Methods
Mice. Generation of the L9'S strain, by replacing the native 4 subunit of the nicotinic acetylcholine receptor (nAChR) with a mutated form, was previously described (6, 17) . Two lines of knock-in mice were generated by injection of mutated ES cells into C57BL/6 blastocysts, one with the neomycin-cassette still present (neomycin-intact), which were studied here, and the other with the neomycin-cassette deleted (neomycin-deleted) via cre recombination in ES cells.
Young adult (3 -8 months) male and female mice heterozygous for the L9'S mutation and their wildtype littermates were used for behavioral, histological and immunocytochemical studies. For electrophysiological recordings in acute midbrain slices, we used P 12 to P 25 pups. All experiments were performed following NIH and local institutional guidelines for the humane treatment of laboratory animals. Genotyping was performed as described (17).
Drugs. All drugs were purchased from Sigma-Aldrich (Sigma-Aldrich, USA) and dissolved as suggested by the manufacturer.
Histology and immunocytochemistry. Each mouse was fixed by cardiac perfusion (0.1M PBS and 4% formaldehyde), postfixed for 2 h and dehydrated in 15 % sucrose and 30 % sucrose. 10 series of cryosections of 30 µm thickness were prepared in coronal orientation.
All stainings were performed free floating. Alternate sections were Nissl stained. Brain sections were qualitatively examined at low magnification (50 X and 100 X) to assess the gross neuroanatomical structure of L9'S and wildtype mice. Double staining was performed with antisera for TH 1:100 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and 4 nAChR 1:100 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and fluorescent secondary antibodies (1:500, Alexa 594, Alexa 488, Molecular Probes, Eugene, OR, USA) respectively using one series of sections for 4 and two series for TH staining (every10 th or every 5 th section counted).
For cell counts, sections were stained for indirect immunohistochemistry according to the VECTASTAIN ABC Elite kit protocol (Vector Laboratories, Burlingame, CA).
Diaminobenzidine was used as chromogen with nickel enhancement. Images were obtained from a total of 8 L9'S and 8 wildtype mice. Cell counts were performed in all midbrain sections containing substantia nigra and ventral tegmental area with fibers of the third cranial nerve separating the two regions. Cell counts were corrected for cell diameter and slice thickness according to the Abercrombie formula (1).
In addition, non-biased stereological cell counts were performed using the optical disector Recordings from dopaminergic neurons in midbrain slices. WT or L9'S Mice aged P 12 -P 25 were used for electrophysiological experiments. Animals were anesthetized using halothane.
The brains were immediately removed, rinsed and transferred to ice-cold artificial cerebrospinal fluid (ACSF), which had been equilibrated for 1 hour. Slices (300 µm-thick) were cut on a vibratome (Leica, Germany or Dosaka, Japan) in coronal orientation. After sectioning, slices were recovered in oxygenated ACSF containing 1 mM kynurenic acid at 32 °C for 0.5 h, and subsequently for at least 0.5 hr in ACSF without kynurenic acid in an oxygenated holding chamber at room temperature and then transferred into a recording chamber. The recording chamber was mounted on the stage of an upright microscope (Zeiss, Germany or Olympus, USA) equipped with infrared video microscopy (Hamamatsu, Japan). Drug application was performed using a gravity driven 8-channel perfusion system (BioMedical Instruments, Germany) for ~ 5 s. Responses to nicotine and GABA were measured during 5 s starting 10 s before drug application and during 5 s starting 5 s after the onset of application each. In addition, we employed local pressurized drug application using a Picospritzer II (General Valve / Parker, USA) to investigate the effects of local and fast drug application. All drugs were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA).
Data are displayed as mean ± S.E.M.
Results

Histology and immunocytochemistry.
Immunoreactivity for TH has been used to quantify catecholaminergic neurons (22, 27, 32). TH is the rate-limiting enzyme for the production of dopamine or noradrenalin. In substantia nigra pars compacta of L9'S mice compared with WT mice, the reduction of TH positive cells is 39% at 4 months and 37% at 8 months (Fig. 1A,B) , substantially greater than the 17% loss of Nissl stained cell bodies ( As another control region in the brainstem, we studied the locus coeruleus which also bears a high density of catecholaminergic (noradrenergic) neurons. The locus coeruleus of L9'S mice displayed no reduction of Nissl stained (data not shown) or TH immunoreactive cells (Fig. 2) . Thus, the loss of dopaminergic neurons in substantia nigra seems to be fairly specific among catecholaminergic neurons in the brainstem. Previous surveys in several other brain areas of L9'S mice also indicated no major changes in neuronal cell numbers as detected by Nissl stain (6) In addition, measurements of dopaminergic innervation revealed that L9'S mice have ~40% reduction of TH-immunoreactivity in the striatum. The dopaminergic innervation of nucleus accumbens is not altered compared to WT (Fig. 3) .
Expression of 4-containing nAChRs
Immunocytochemistry for the 4 subunit revealed a general reduction of 4 immunoreactivity in cells including hippocampus, cortex, and striatum (data not shown). This reduction is consistent with previous epibatidine binding data, which shows that the intact neo cassette reduces expression of the mutated allele by ~75% in the entire brain, corresponding to nearly a two-fold reduction of total 4 subunit expression in the heterozygotes studied here (6) and presumably does not arise from cell loss. Also consistent with reduced expression of the mutant allele, individual surviving 4-immunoreactive cells in substantia nigra and locus coeruleus showed a substantial reduction of 4 immunoreactivity. This per-cell decrease of immunoreactivity was distinct from the numerical loss of substatia cells that stained for Nissl or TH ( Fig. 1 and 2 ). (Fig. 4) .
Locomotor effects of dopaminergic deficits
Recordings in midbrain slices: dopaminergic cells.
A major goal was to ask whether dopaminergic neuron death is related to increased excitation during cholinergic stimulation. Patch-clamp analysis of dopaminergic neurons in acute midbrain slices is an appropriate method to gather supporting evidence. Because we believe that at least one consequence of hypersensitive nicotinic receptors is cholinergic excitotoxicity, analyses of spontaneous and drug-induced activity was performed. We conducted most of our experiments with nicotine, because we wished to verify that the effects occur at nicotinic rather than muscarinic receptors.
Voltage-clamp analyses showed that hyperpolarization-induced currents (I h ) did not differ between cells of L9'S and WT mice (Fig. 5B) . However, there was a small but significantly (p < In current-clamp experiments on L9'S slices, application of nicotine (10 -1000 µM) resulted in a robust depolarization of dopaminergic neurons and an increase in spiking behavior (Fig. 6A) . In contrast, dopaminergic neurons of WT mice initially showed a hyperpolarization and a reduction in spiking behavior (Fig. 6B) . These different responses of L9'S and WT dopaminergic (I h -positive) midbrain neurons were significant (Fig. 7A,B) . The differences were more pronounced at 10 µM than at 100 µM nicotine, presumably because the higher nicotine dose partially desensitized both L9'S and WT receptors. When higher doses of nicotine were applied to L9'S cells, membrane conductance increased irreversibly indicating cell death.
In voltage-clamp mode, we were not able to detect significant drug responses in L9'S or WT cells (data not shown). Since we were concerned that lack of specific nicotine-induced currents was related to a rather slow perfusion system, we also employed a local pressurized system. Again, even this fast and local application did not reveal any specific nicotine responses (in voltage clamp) in mutant and WT cells (Fig. 6C) .
As a positive control, we applied GABA (10 µM), which induced robust outward currents (Fig. 6D) , indicating that the failure to generate nicotine-induced currents was not due to technical factors. We also verified that the responses to GABA in dopaminergic cells displayed no differences between the L9'S and WT genotypes (Fig. 7C,D) .
Recordings in midbrain slices: non-dopaminergic cells.
Non-dopaminergic L9'S neurons within substantia nigra displayed an increase in spiking frequency at 10 µM nicotine (Fig. 7B) , while WT neurons displayed transient decreases. This pattern resembles that for dopaminergic neurons. At 100 M nicotine, both L9'S and WT neurons continued to display nicotine-induced increases in firing frequency, and there was no difference between the two genotypes. We chose not to pursue RMP measurements for nondopaminergic cells, because the high firing rate of such neurons invalidates the definition of resting potential.
Discussion
Our present data with the L9'S strain support the hypothesis that increased cholinergic input to dopaminergic neurons is a possible mechanism underlying dopaminergic neuron death.
Despite the low expression level of the mutant allele (6) (necessary to retain viability), dopaminergic neurons are reduced in number, resulting in decreased striatal dopaminergic innervation and a loss of amphetamine-induced locomotion in heterozygous mutant mice.
It is interesting that only dopaminergic neurons of substantia nigra are affected while dopaminergic neurons in VTA seem to remain intact. This study did not investigate the mechanisms accounting for this differential effect. In Parkinson's disease as well as in several other animal models of dopaminergic cell death (e. g. MPTP-mouse, weaver-mouse), cell death is more extensive in substantia nigra than in ventral tegmental area. Nicotinic AChRs may be among the genes whose differential expression accounts for this differential vulnerability among dopaminergic neurons.
As expected from the widespread distribution of 4 subunits, we detected immunoreactivity for 4 subunits in areas outside midbrain. Previous studies revealed no cell death outside of the midbrain (7, 17) . Although only substantia nigra shows appreciable cell A hypersensitive 7 nicotinic strain also shows neuronal death and, in homozygotes, neonatal lethality (25). Therefore severe CNS cholinergic excitotoxicity can occur as a consequence of gain of mutations in at least two distinct nAChR subunits (19).
Circuit-based nicotinic neurotoxicity
Is the concept of increased cholinergic activation of substantia nigra dopaminergic neurons altering their function or viability relevant to the pathophysiology of Parkinson's disease? We believe that this is so. Parkinson's disease is characterized by the loss of dopaminergic neurons in substantia nigra, resulting in dopamine deficiency within the striatum.
Further downstream, striatal dopamine deficiency leads to increased activity of the subthalamic nucleus and the internal segment of the globus pallidus. In rodents, there are both a direct pathway from the subthalamic nucleus to substantia nigra pars compacta (14) , and also an indirect excitatory pathway from subthalamic nucleus via the pedunculopontine nucleus to substantia nigra pars compacta (9) . The latter employs both glutamate and acetylcholine as neurotransmitters. In states of dopamine deficiency, one expects the increased activity in subthalamic nucleus to produce an increased cholinergic drive of dopaminergic neurons in substantia nigra. Most interestingly, lesioning the pedunculopontine nucleus has substantial protective effects in MPTP-treated parkinsonian monkeys (29). In summary, cholinergic excitotoxicity potentially represents a self-reinforcing mechanism that arises from basal ganglia 
Dopaminergic vs non-dopaminergic neurons
Our electrophysiological experiments provide evidence that dopaminergic neurons of 
Comparison with previous electrophysiological data
We were initially surprised to find no reproducible excitatory nicotine responses in WT dopaminergic neurons as reported previously (16, 26), although we have experimented with various drug application systems including fast application systems. Instead, in our hands, WT dopaminergic neurons showed a hyperpolarization and reduction in spiking frequency during application of moderate doses of nicotine (10 µM). However, it is not impossible that responses reported in the previous studies represent indirect effects on dopaminergic neurons, since the latency between fast local drug application and change in current was unusually long (16, 26).
We have preliminary evidence that nicotinic 4 mediated responses can occur within < 100 ms after fast application of nicotine in a new strain of mutant mice (data not shown). However, we are aware that the electrophysiological data presented here do not prove that excitatory effects in L9'S animals are caused by nicotinic receptors located on dopaminergic neurons themselves. We will address this question in future studies.
Contrast with the neuroprotective effects of nicotine
Our findings present a contrast with the potential neuroprotective properties of nicotine. 
